XT
TVTX icon

XTX Topco’s Travere Therapeutics TVTX Stock Holding History

XTX Topco’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$254K Sell
8,546
-52,134
-86% -$1.56M ﹤0.01% 2623
2025
Q4 		$2.32M Buy
60,680
+50,127
+475% +$1.63M 0.06% 466
2025
Q3 		$252K Buy
+10,553
New +$198K 0.01% 1649
2025
Q2 		– Sell
-52,202
Closed -$935K – 3189
2025
Q1 		$935K Buy
52,202
+23,069
+79% +$468K 0.05% 606
2024
Q4 		$507K Buy
29,133
+14,928
+105% +$264K 0.04% 758
2024
Q3 		$199K Sell
14,205
-40,057
-74% -$417K 0.01% 1447
2024
Q2 		$446K Buy
54,262
+28,480
+110% +$192K 0.04% 713
2024
Q1 		$199K Sell
25,782
-46,607
-64% -$393K 0.03% 1182
2023
Q4 		$651K Buy
72,389
+37,097
+105% +$270K 0.14% 136
2023
Q3 		$316K Buy
35,292
+12,393
+54% +$175K 0.05% 693
2023
Q2 		$352K Buy
+22,899
New +$417K 0.06% 603

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

XTX Topco's TVTX Position: Q1 2026 in Review

XTX Topco reduced its Travere Therapeutics (TVTX) stake by 86% in Q1 2026, selling an estimated $1.56M and leaving 8,546 shares worth $254K. The position accounts for ﹤0.01% of the portfolio, ranked #2623.

XTX Topco first reported a position in TVTX in Q2 2023 and has held it in 11 quarters since. The position peaked at $2.32M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • XTX Topco held 8,546 shares of Travere Therapeutics worth $254K as of Q1 2026.
  • XTX Topco sold 52,134 Travere Therapeutics shares in Q1 2026, an estimated $1.56M.
  • Travere Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #2623 holding.
  • XTX Topco first reported a position in Travere Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • XTX Topco's Travere Therapeutics position peaked at $2.32M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.